An indirect treatment comparison of efficacy and health-related quality of life following treatment with idecabtagene vicleucel versus belantamab mafodotin in triple-class exposed relapsed/refractory patients with multiple myeloma

Click to increase image sizeClick to decrease image size

Acknowledgments

The authors received editorial assistance in the preparation of this manuscript from Eilish McBurnie, PhD, of Excerpta Medica, funded by Bristol Myers Squibb. The authors are fully responsible for all content and editorial decisions for this manuscript.

Author contributions

P.R.O., F.E.D., M.D., K.W., and K.K. conceived and designed the study, and contributed to the interpretation and analysis of data. K.T., S.C., C.C., D.A., and A.M. contributed to the acquisition, interpretation, and analysis of data. T.M. and J.B. contributed to the interpretation and analysis of data. J.F. and D.D. conceived and designed the study, and contributed to the acquisition, interpretation, and analysis of data. All authors have read and agreed to the final published version of the manuscript.

Disclosure statement

P.R.O. has served on advisory boards for Amgen, Bristol Myers Squibb, GlaxoSmithKline, Janssen, Kite Pharma, Oncopeptides, Pfizer, Sanofi, and Takeda, has provided consultancy to AbbVie, Bristol Myers Squibb, and Roche, and has received honoraria from Amgen, Bristol Myers Squibb, GlaxoSmithKline, Janssen, Regeneron, Sanofi, and Takeda. K.T., S.C., C.C., and A.M. are employees of PRECISIONheor, which received funding from Bristol Myers Squibb to conduct this study. F.E.D. has served on advisory boards for and provided consultancy to Amgen, Bristol Myers Squibb, GlaxoSmithKline, Janssen, Oncopeptides, Sanofi, and Takeda. M.D. has served on advisory boards for Bristol Myers Squibb and Takeda, has provided consultancy to and received honoraria from Amgen, Bristol Myers Squibb, GlaxoSmithKline, Janssen, Sanofi, and Stemline, and has received grants from Janssen. K.W. has received honoraria from AbbVie, Adaptive Biotechnologies, Amgen, AstraZeneca, BeiGene, Bristol Myers Squibb, GlaxoSmithKline, Janssen, Karyopharm Therapeutics, Novartis, Oncopeptides, Pfizer, Roche Pharma, Sanofi, Stemline, and Takeda, has provided consultancy to AbbVie, Adaptive Biotechnologies, Amgen, BeiGene, Bristol Myers Squibb, GlaxoSmithKline, Janssen, Karyopharm Therapeutics, Oncopeptides, Pfizer, Roche Pharma, Sanofi, and Takeda, and has received research funding (institution) from AbbVie, Amgen, Bristol Myers Squibb, GlaxoSmithKline, Janssen, and Sanofi. T.M., K.K., J.B., and D.D. are employees of and have equity in Bristol Myers Squibb. D.A. was formerly an employee of PRECISIONheor, which received funding from Bristol Myers Squibb to conduct this study. J.F. was formerly an employee of and has equity in Bristol Myers Squibb and is currently an employee of Pfizer.

Data availability statement

Bristol Myers Squibb details the data sharing process via the following website: https://www.bms.com/researchers-and-partners/independent-research/data-sharing-request-process.html

Additional information

Funding

This work was supported by Bristol Myers Squibb.